| Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer MJ Watt, AK Clark, LA Selth, VR Haynes, N Lister, R Rebello, LH Porter, ... Science translational medicine 11 (478), eaau5758, 2019 | 306 | 2019 |
| Patient-derived models of abiraterone-and enzalutamide-resistant prostate cancer reveal sensitivity to ribosome-directed therapy MG Lawrence, D Obinata, S Sandhu, LA Selth, SQ Wong, LH Porter, ... European urology 74 (5), 562-572, 2018 | 107 | 2018 |
| Systematic review links the prevalence of intraductal carcinoma of the prostate to prostate cancer risk categories LH Porter, MG Lawrence, D Ilic, D Clouston, DM Bolton, M Frydenberg, ... European urology 72 (4), 492-495, 2017 | 105 | 2017 |
| The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer RJ Rebello, E Kusnadi, DP Cameron, HB Pearson, A Lesmana, JR Devlin, ... Clinical Cancer Research 22 (22), 5539-5552, 2016 | 87 | 2016 |
| The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology GP Risbridger, AK Clark, LH Porter, R Toivanen, A Bakshi, NL Lister, ... Nature communications 12 (1), 5049, 2021 | 58 | 2021 |
| Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate‐tolerant cells LH Porter, K Hashimoto, MG Lawrence, C Pezaro, D Clouston, H Wang, ... BJU international 121 (6), 971-978, 2018 | 55 | 2018 |
| Establishment of primary patient‐derived xenografts of palliative TURP specimens to study castrate‐resistant prostate cancer MG Lawrence, DW Pook, H Wang, LH Porter, M Frydenberg, ... The Prostate 75 (13), 1475-1483, 2015 | 45 | 2015 |
| Knowing what’s growing: why ductal and intraductal prostate cancer matter MG Lawrence, LH Porter, D Clouston, DG Murphy, M Frydenberg, ... Science translational medicine 12 (533), eaaz0152, 2020 | 34 | 2020 |
| Establishing a cryopreservation protocol for patient‐derived xenografts of prostate cancer LH Porter, MG Lawrence, H Wang, AK Clark, A Bakshi, D Obinata, ... The Prostate 79 (11), 1326-1337, 2019 | 24 | 2019 |
| Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models LH Porter, JJ Zhu, NL Lister, SG Harrison, S Keerthikumar, DL Goode, ... Nature Communications 14 (1), 5346, 2023 | 21 | 2023 |
| CX-5461 sensitizes DNA damage repair–proficient castrate-resistant prostate cancer to PARP inhibition MG Lawrence, LH Porter, N Choo, D Pook, JP Grummet, CJ Pezaro, ... Molecular cancer therapeutics 20 (11), 2140-2150, 2021 | 18 | 2021 |
| Androgen receptor enhancer amplification in matched patient‐derived xenografts of primary and castrate‐resistant prostate cancer LH Porter, A Bakshi, D Pook, A Clark, D Clouston, J Kourambas, ... The Journal of pathology 254 (2), 121-134, 2021 | 18 | 2021 |
| The future of patient-derived xenografts in prostate cancer research MG Lawrence, RA Taylor, GB Cuffe, LS Ang, AK Clark, DL Goode, ... Nature Reviews Urology 20 (6), 371-384, 2023 | 11 | 2023 |
| Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Sci Transl Med 11: eaau5758 MJ Watt, AK Clark, LA Selth, VR Haynes, N Lister, R Rebello, LH Porter, ... | 6 | 2019 |
| Hidden clues in prostate cancer–Lessons learned from clinical and pre-clinical approaches on diagnosis and risk stratification R Toivanen, LH Porter, Z Li, D Clouston, GP Risbridger, RA Taylor Cancer Letters 524, 182-192, 2022 | 5 | 2022 |
| Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies LH Porter, SG Harrison, GP Risbridger, N Lister, RA Taylor The Journal of Steroid Biochemistry and Molecular Biology, 106571, 2024 | 2 | 2024 |
| Co‐targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor‐null prostate cancer N Choo, S Keerthikumar, S Ramm, D Ashikari, L Teng, B Niranjan, ... The Journal of Pathology 263 (2), 242-256, 2024 | 2 | 2024 |
| Defining the challenges and opportunities for using patient‐derived models in prostate cancer research WN Brennen, C Le Magnen, S Karkampouna, N Anselmino, N Bock, ... The Prostate 84 (7), 623-635, 2024 | 1 | 2024 |
| Preclinical Evidence of the Efficacy of Lewis Y Car T Cells in Patient-Derived Models of Prostate Cancer GP Risbridger, LH Porter, J Zhu, D Byrne, N Lister, A Azad, M Hofman, ... Journal of the Endocrine Society 5 (Supplement_1), A1029-A1030, 2021 | 1 | 2021 |
| Abstract PR005: CX-5461 sensitizes DNA damage repair-proficient castrate-resistant prostate cancer to PARP inhibition MG Lawrence, LH Porter, N Choo, E Sanij, R Taylor, R Pearson, ... Molecular Cancer Therapeutics 23 (6_Supplement), PR005-PR005, 2024 | | 2024 |
